Takahiro Kirisawa, Akiko Maeshima, Nao Kikkawa, Eijiro Nakamura, Tatsunori Shimoi, Aiko Maejima, Toru Imai, Hiroki Hagimoto, Tomoya Okuno, Ayumu Matsuda, et al. Prognostic Factors for Patients With Urachal Carcinoma Undergoing Radical Surgery: Risk Stratification for Future Prospects of Precision Oncology. JU Open Plus. 2024. 2. 9
Rui Kitadai, Tatsunori Shimoi, Shu Yazaki, Hitomi Sumiyoshi Okuma, Mai Hoshino, Munehiro Ito, Ayumi Saito, Shosuke Kita, Yuki Kojima, Tadaaki Nishikawa, et al. Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine. Breast cancer (Tokyo, Japan). 2024
大西 舞, 下井 辰徳, 小島 勇貴, 矢崎 秀, 山中 太郎, 北台 留衣, 河知 あすか, 大熊 ひとみ, 齋藤 亜由美, 伊藤 宗洋, et al. 乳癌におけるTROP2とHER2の発現および共発現パターン 二重特異性抗体薬物複合体治療への示唆(Expression and co-expression patterns of TROP2 and HER2 in breast cancer: implications for bispecific antibody-drug conjugate therapy). 日本乳癌学会総会プログラム抄録集. 2024. 32回. 51-51
IMAI Toru, SHIMOI Tatsunori, KOJIMA Yuki, KAWACHI Asuka, OKUMA SUMIYOSHI Hitomi, HOSHINO Mai, ITO Munehiro, SAITO Ayumi, KITA Shosuke, MAEJIMA Aiko, et al. Third-line chemotherapy for recurrent/refractory rhabdomyosarcoma in adults: a single-center retrospective study. 日本臨床腫瘍学会学術集会(CD-ROM). 2024. 21st
ANDO Mark M., SHIMOI Tatsunori, IMAI Toru, KOJIMA Yuki, SUDO Kasuki, YONEMORI Kan. Clinical outcome of treatment rechallenge with HER2-directed antibody-drug conjugate in metastatic breast cancer. 日本臨床腫瘍学会学術集会(CD-ROM). 2024. 21st